Novartis readies for FDA review of $1 billion CAR-T child cancer hope – Reuters
Reuters |
Novartis readies for FDA review of $1 billion CAR–T child cancer hope
Reuters They began with several molecules, but finally settled on one, called 4-1BB, because it seemed to prime the human immune system to attack blood cancer more aggressively than others. "Our first tests convinced us these T cells were special," Campana … Novartis CAR–T safety in FDA spotlight Novartis' CAR–T Therapy for Pediatric Leukemia to Face FDA Advisory Panel |
